Shenzhen Hepalink Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

0.92

EPS

—

Div Yield, %

7.95%

Shrs. gr., 5y

3.30%

Rev. gr., 5y

2.49%

Revenues

5.45b

-23.94%

Net income

-783m

CFO

398m

Dividend

May 24, 20230.11215 HKD/sh

Profile

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

URL

https://www.hepalink.com/

IPO date

May 06, 2010

Employees

2,366

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	5,445,572 -23.94%	7,159,411 12.48%	6,365,177 19.38%
Cost of revenue	4,420,062	5,742,148	5,126,073
Unusual Expense (Income)
NOPBT	1,025,510	1,417,262	1,239,105
NOPBT Margin	18.83%	19.80%	19.47%
Operating Taxes		115,164
Tax Rate		8.13%
NOPAT	1,025,510	1,302,099	1,239,105
Net income	(783,258) -207.68%	727,426 202.10%	240,788 -76.49%
Dividends	(425,890)	(51,355)	(220,094)
Dividend yield	2.48%	0.27%	0.88%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	3,624,575	4,056,474	3,299,920
Long-term debt	1,990,855	2,518,177	2,458,271
Deferred revenue	30,426	32,547	16,673
Other long-term liabilities	45,425	61,873	147,089
Net debt	835,627	1,971,764	196,085
Cash flow
Cash from operating activities	398,216
CAPEX	(444,878)
Cash from investing activities	1,221,569	249,840	719,928
Cash from financing activities	(1,202,972)	329,564
FCF	2,727,709	(705,248)	403,552
Balance
Cash	2,265,826	3,450,422	3,925,414
Long term investments	2,513,977	1,152,465	1,636,692
Excess cash	4,507,525	4,244,916	5,243,848
Stockholders' equity	3,085,724	6,721,513	5,790,098
Invested Capital	14,503,519	14,579,278	11,938,701
ROIC	7.05%	9.82%	10.60%
ROCE	5.75%	7.40%	7.10%
EV
Common stock shares outstanding	1,467,325	1,467,296	1,467,296
Price	11.69 -9.03%	12.85 -24.85%	17.10 -0.70%
Market cap	17,153,028 -9.03%	18,854,756 -24.85%	25,090,765 7.67%
EV	18,063,884	20,923,244	25,398,811
EBITDA	1,399,106	1,724,922	1,541,850
EV/EBITDA	12.91	12.13	16.47
Interest	238,696	235,242	201,631
Interest/NOPBT	23.28%	16.60%	16.27%